Viewing Study NCT02508532

Bugs

Ignite Creation Date: 2025-12-24 @ 9:55 PM

Ignite Modification Date: 2026-01-03 @ 11:04 PM

Study NCT ID: NCT02508532

Status: COMPLETED

Last Update Posted: 2022-06-21

First Post: 2015-07-23

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Sponsor: Blueprint Medicines Corporation

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions:

Condition Brief	Condition Text	View

None	Gastrointestinal Stromal Tumors (GIST)	View
None	Other Relapsed or Refractory Solid Tumors	View

Keywords:

Keyword Brief	Keyword Text	View

None	2L GIST	View
None	GIST second line	View
None	GIST gleevec	View
None	GIST imatinib	View
None	Second-line GIST clinical trial	View
None	BLU-285	View
None	BLU 285	View
None	BLUE-285	View
None	BLUE 285	View
None	Avapritinib	View
None	GIST imatinib relapse	View
None	GIST gleevec relapse	View
None	GIST KIT	View
None	GIST relapse	View
None	GIST refractory	View
None	GIST imatinib intolerance	View
None	GIST TKI treatment	View
None	GIST tyrosine kinase inhibitor treatment	View
None	GIST TKI	View
None	GIST tyrosine kinase inhibitor	View
None	Advanced GIST	View
None	GIST mutations	View
None	GIST treatments	View
None	Blueprint GIST	View
None	Relapsed GIST clinical trial	View
None	Refractory GIST clinical trial	View
None	KIT-mutant GIST	View
None	cancer gist	View
None	gastrointestinal stromal tumor	View
None	gist cancer	View
None	PDGFRA	View